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INTRODUCTION
Multiple sclerosis (MS) is a chronic
demyelinating inflammatory disease of the
central nervous system (CNS) affecting
prevalently young adults (1, 2). The patho-
genesis of MS has long been attributed to
self-reactive T cells but recently the relevant
role of B cells has also been recognized (2,
3). Furthermore, it has been demonstrated
that innate immunity has a pivotal role in
the beginning and in advanced stages of MS
(4–6).
Innate immunity represents the imme-
diate non-specific defense against infec-
tions and dangerous agents acting through
its essential arms such as inflammation and
blood coagulation (7–10). The coagulant
processes are normally balanced by the nat-
ural anti-coagulant system needed to limit
the host damage, and their imbalance leads
to venous thrombosis (7, 8).
Many evidences reported below sup-
port a significant presence of local and
systemic thrombotic events in MS confirm-
ing the global over-stimulation of innate




CEREBRAL THROMBOSIS IN MS
Several extensive studies have shown the
association between venous thromboem-
bolism and MS from its early stages. In a
large population-based cohort study eval-
uating data from a 30-year Danish National
Registry, MS was associated with increased
long-term risk of venous thromboem-
bolism (11). Another paper, based on the
review of one cohort study and three cross-
sectional studies, found that early MS was
associated with an increased risk of pul-
monary embolism, deep venous throm-
boembolism, and stroke, both the latter
persisting over time (12). Other large stud-
ies have shown an increased risk of venous
thromboembolism in MS as well as in
several other immune-mediated illnesses
(13–15).
Cases of cerebral thrombosis have been
also reported in MS, mainly attributed
to the effect of lumbar puncture and
methylprednisolone therapy, however, in
some cases no pre-disposing condition was
found (16–19).
Moreover, a collaborative genome-wide
association study screen in MS patients, not
only implicated a multitude of genes cod-
ing for cytokine pathway, co-stimulatory,
and signal transduction molecules of
immunological relevance, but also for a
vascular cell adhesion molecule (VCAM1)
mediating leukocyte–endothelial cell adhe-
sion and signal transduction (20). Interest-
ingly, thrombin is able to induce expres-
sion of functional forms of VCAM1 on
endothelial cells (21) and this expression
can be inhibited by the specific thrombin
inhibitor, hirudin. In my opinion, these
data may further support the association
between coagulation system and inflam-
mation as well as between components of
innate and adaptive immunity in MS.
PRO-THROMBOTIC CONDITIONS AND
VASCULAR DYSFUNCTIONS IN MS
There are several studies confirming
platelet (22–24) and complement (25–27)
involvement in MS, both essential for the
innate immune response by linking inflam-
mation and coagulation. Moreover, many
vascular dysfunctions have been reported
in MS. They have been largely resumed in
the review of D’Haeseleer and colleagues
(28) facilitating their discussion in the
restricted space of this work.
Vascular risk factors in MS
Interestingly, in the review of D’Haeseleer
and colleagues, all the vascular risk fac-
tors reported to be associated with MS
such as reduced physical activity, smoking,
endothelial dysfunction,platelet activation,
thrombophilia, and hyper-homocysteine
are essentially pro-thrombotic conditions.
Conversely, other vascular risk factors such
as atrial fibrillation, flutter, arterial hyper-
tension, diabetes mellitus, dyslipidemia,
and obesity have not been associated with
MS (28).
Cerebral hypoperfusion in MS
Decreased cerebral blood volume and flow,
as well as its prolonged brain mean tran-
sit time, were demonstrated in all forms
of MS and even in clinically isolated
syndrome, both in white and gray mat-
ter, by SPECT, PET, and dynamic sus-
ceptibility contrast-enhanced MRI (28).
In my opinion, the widespread cerebral
hypoperfusion in MS may be prevalently
determined by the blood flow deceler-
ation in the venous bed due to the
inflammatory-thrombotic processes. This
consequently leads to decreased arterial
flow with reduced tissue oxygenation and
energy metabolism clarifying the similari-
ties between ischemic and MS lesions for
both the histopathological features and
enhanced expression of hypoxia-inducible
factors mentioned by D’Haeseleer et al.
This explanation of cerebral hypoperfusion
appears to be more effective compared to
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both reduced axonal activity and decreased
astrocyte energy metabolism proposed in
the review as the possible explanation for
hypoperfusion.
Venous blood drainage
According to D’Haeseleer et al., I think
that MS could unlikely be caused by the
obstructed extracranial venous drainage.
The CCSVI theory explains the perivenu-
lar pattern of MS lesions by extrava-
sation and degradation of erythrocytes
due to blocked venous drainage with
consequent iron deposition causing the
inflammatory demyelinating lesions. How-
ever, the perivenular distribution of MS
lesions, named “Dawson’s fingers,” preva-
lently around the ventricle-based brain
veins, has long been thought to be
the result of inflammation and coagula-
tion around the major axis of medular
veins (29).
Following the first single center study
(30), many groups have tried to replicate
their findings, but largely without success.
Two recent studies from Italy (31) and
Canada (32) provide further evidence to
refute the idea of CCSVI as a cause of MS.
Even the short-lasting improvements
reported by many operated patients that
were considered placebo effect by the
authors of the review (28), may be partly
attributable to the intra-operatory intra-
venous and 3-week subcutaneous low-
weight heparin therapy according to Zam-
boni’ protocol (33), since heparin has been
used with some success in MS in the
60s (34, 35). However, further studies are
needed in order to confirm this hypothesis.
Nevertheless, in my opinion, several
studies carried out to test this theory have
indirectly demonstrated the presence of
the widespread endothelial damage likely
due to the persistence of inflammatory-
thrombotic processes. The emerging evi-
dences on the link of jugular venous reflux
with several CNS diseases have not clar-
ified their cause–effect relationship (36),
however, the venous dysfunctions seem to
be the common consequence of inflam-
matory processes on the vascular endothe-
lium rather than the unique anatomic
cause of different disorders. Interestingly,
a reduction in venous vasculature vis-
ibility on susceptibility-weighted imag-
ing venography was already demonstrated,
thus suggesting a correlation with both
a decrease in metabolism and venous
morphological alterations in the brain
(37). These manifestations could cor-
relate to endothelial injury determined
by long-term inflammatory-thrombotic
processes rather than to the stenosis of
extracranial veins. The latter should deter-
mine brain venous engorgement in con-
trast with reduced visibility of venous
vasculature.
More convincingly, Kirk and colleagues
much earlier found the microvascular
endothelial tight junctions abnormalities
in vessels of any size, especially in active
lesions as compared to normal appearing
white matter, supporting a causative role of
diffusible inflammatory mediators (38). In
fact, the inflammatory factors increase the
endothelial permeability and the expres-
sion of adhesion molecules determining
the extravasation of immune cells and
erythrocytes (7, 8).
ROLE OF COAGULATION SYSTEM IN MS AND
IN EXPERIMENTAL ALLERGIC
ENCEPHALOMYELITIS
Many evidences in literature support the
role of the coagulation system as an
expression of innate immune activation
both in MS and in experimental allergic
encephalomyelitis (EAE).
In 1935, Putnam already proposed the
pivotal role of venule thrombosis in MS
(39). Another pathological study in acute
MS reported fibrin deposition on endothe-
lial cells in many thin veins and capillaries
in areas without myelin damage or reactive
parenchymal changes, with some throm-
bosed vessels or even intra-cerebral hemor-
rhage (40). Moreover, coagulation proteins
were detected within chronic active plaques
in MS (41).
Chapman highlighted the relevance
of thrombin in inflammatory brain dis-
eases (42, 43). Thrombin has numer-
ous hormone-like functions modulating,
among other, microglia and astrocytes
(44). The activity of thrombin in the brain
is regulated by thrombin inhibitors such as
serum antithrombin III and brain protease
nexin-1 secreted by glial cells and neurons
that confirms the relevance of thrombin
regulation in the brain (42, 43). An increase
of brain protease nexin-1 levels was shown
at early pre-clinical stages in EAE (45)
while the plasma thrombin–antithrombin
complexes increased immediately prior to
EAE symptoms and decreased in relation
to their improvement (46).
The activated microglia, a cellular com-
ponent of innate immunity in the brain,
along with fibrin deposition, were both
found in acute/early MS and in rat EAE
lesions, representing a first stage of tis-
sue injury before active demyelination
and massive T-cell infiltration (47). Fibrin
deposition preceded and regulated inflam-
matory demyelination, as well as genetic or
pharmacological fibrin depletion amelio-
rated both clinical symptoms and inflam-
matory response in EAE (48). Likewise,
hirudin or recombinant activated protein
C improved EAE and suppressed pro-
inflammatory T-helper1 and T-helper17
cytokines in astrocytes and immune cells
(41). The suppression of EAE by dermatan
sulfate (49) or low doses of heparins (50)
has been long demonstrated.
All reported here data highlight that the
activation of coagulation system, linked to
innate immunity, is a mandatory process
during the early immune reaction toward
the tissue damage of any kind. This reac-
tion is independent of the underlying
cause of injury and precedes a specific
adaptive immune response in both MS
and EAE.
DISCUSSION
Although the histopathological studies
have only rarely found cerebral venous
thrombosis in MS, there is convinc-
ing evidence supporting the presence of
inflammatory-thrombotic processes dur-
ing the overall course of the disease, from
its early phases. This might confirm the
relevant role of innate immunity in MS
not only for its inflammatory component
(4–6, 47), but also for the coagulant one.
These manifestations are present both in
the brain and at peripheral level reflecting
a systemic stimulation of innate immu-
nity by unknown exogenous factors that
may be represented by viral infections (51).
In fact, even if the etiology of MS still
remains unexplained, viral infections are
considered the main environmental factors
related to MS as suggested by their associa-
tion with disease exacerbations (52) as well
as by many epidemiological studies and the
common presence of oligoclonal IgG in the
cerebrospinal fluid of MS patients (51) and
by their relevance as non-heritable factors
in gene–environment interactions (53).
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The early systemic activation of innate
immunity suggests a direct triggering by
pathogens rather than by an indirect
autoimmune CNS reaction. The innate
immunity not only stimulates and mod-
ulates adaptive immunity at the beginning
of disease but also mediates the neurode-
generative changes in progressive phase of
MS (5, 6). While many efforts are aimed
to better define the function of the innate
immune cells in order to modulate their
potential therapeutic action in MS (5, 6),
the coagulant component of innate immu-
nity, well studied in animals, is not suffi-
ciently evaluated in humans.
The physiological innate immune
response to infections does not usu-
ally determine the thrombotic manifes-
tations due to an effective action of
the natural anti-coagulant system. How-
ever, thrombotic manifestations can take
place when the natural anti-coagulant
system fails to counterbalance the pro-
longed or intense coagulation processes.
These conditions may occur occasionally
in immune-competent people during par-
ticularly severe infections, or may manifest
persistently during chronic latent infec-
tions occurring in individuals with unreg-
ulated immunity and genetic or envi-
ronmentally induced impairment of anti-
coagulant system. MS and other immune-
mediated disorders associated with throm-
boembolism may fall into this last cate-
gory. However, there is no doubt that if the
activation of innate immunity is directly
triggered by viral infection, playing a pro-
tective role against infection, our thera-
peutic intervention should be not greater
than necessary to compensate the reduced
anti-coagulant capacity.
CONCLUSION
Several evidences support persistent
inflammatory-thrombotic processes in
MS confirming the prolonged activation of
innate immunity, likely by chronic latent
infections. Experimental evidences com-
ing from the literature here reported may
open new therapeutic perspectives for
MS patients. In fact, it is already pos-
sible to interfere with the coagulation
system at various levels of the cascade,
and clinical trials trying to transfer the
promising results on EAE to humans are
needed.
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